These genomic abnormalities occur during the transition from MGUS to MM, suggesting that aberrant activation of the non-canonical NF-κB pathway and increased autonomy from the microenvironment are key steps in the malignant progression of MM37,38,41. The gene discussed is NFKB1; the disease is Miyoshi myopathy.